News Kalytera Therapeutics Inc Toronto S.E.

Equities

KLY

CA48349P1036

End-of-day quote Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^PTS	-.--%		-.--%	-.--%

2021	Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	MT
2021	Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	18/08/21	MT
Claritas Pharmaceuticals : IIROC Trading Resumption - CLAS	18/08/21	AQ
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107	18/08/21	GL
Claritas Pharmaceuticals : IIROC Trading Halt - CLAS	18/08/21	AQ
Claritas Announces Grant of Stock Options to Directors and Officers	28/07/21	GL
Claritas Pharmaceuticals : Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	26/07/21	AQ
Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	26/07/21	CI
Reverse Split: 1 of 20	22/07/21	FA
Claritas Pharmaceuticals : Reports Additional Data in Animal Model of Pulmonary Arterial Hypertension Treatment, R-107	21/07/21	MT
Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21/07/21	CI
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21/07/21	GL
Claritas Pharmaceuticals : 1-For-20 Share Consolidation Effective July 23	20/07/21	MT
Claritas Announces Effective Date for Share Consolidation	20/07/21	GL
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) dropped from S&P/TSX Venture Composite Index	19/07/21	CI
Claritas Pharmaceuticals : Announces Commitments from Company's Largest Shareholders to Vote for Approval of Share Consolidation	11/06/21	AQ
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation	10/06/21	GL
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics	01/06/21	GL
Claritas Pharmaceuticals : Announces Settlement of Debt Transaction	31/05/21	AQ
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	28/05/21	CI
Claritas Pharmaceuticals Issues Letter to Shareholders	11/05/21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kalytera Therapeutics Inc Toronto S.E.

Equities

KLY

CA48349P1036

Summary

Filters